Search research articles
Contact Us
Filters
Showing results (491-500 of 542) with videos related to
Page
of 55
Sort By:
Open Forum Infectious Diseases
|
December 1, 2025
Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
Todd Hulgan, Kristine M Erlandson, Yuki Bradford, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 13, 2014
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy
Jeffrey M Jacobson, Hongying Wang, Rebeka Bordi, et al.
The Journal of Infectious Diseases
|
July 29, 2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
Heather J Ribaudo, Huan Liu, Matthias Schwab, et al.
The Journal of Antimicrobial Chemotherapy
|
February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)
Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
The Journal of Antimicrobial Chemotherapy
|
January 23, 2019
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353
Amesika N Nyaku, Lu Zheng, Roy M Gulick, et al.
The Journal of Antimicrobial Chemotherapy
|
June 6, 2018
Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals
Tailah Bernardo de Almeida, Marcelo Costa Velho Mendes de Azevedo, Jorge Francisco da Cunha Pinto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 31, 2001
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy
P G Pappas, J R Perfect, G A Cloud, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 19, 2008
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
C Bradley Hare, John Mellors, Amy Krambrink, et al.
Clinical Pharmacology and Therapeutics
|
April 22, 2019
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Zeruesenay Desta, Roseann S Gammal, Li Gong, et al.
Molecular Psychiatry
|
September 6, 2024
A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder
Marion M Friske, Eva C Torrico, Maximilian J W Haas, et al.
Page
of 55
Search research articles
Search
Showing results (491-500 of 542) with videos related to
Sort By:
Page
of 55
Open Forum Infectious Diseases
|
December 1, 2025
Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
Todd Hulgan, Kristine M Erlandson, Yuki Bradford, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 13, 2014
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy
Jeffrey M Jacobson, Hongying Wang, Rebeka Bordi, et al.
The Journal of Infectious Diseases
|
July 29, 2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
Heather J Ribaudo, Huan Liu, Matthias Schwab, et al.
The Journal of Antimicrobial Chemotherapy
|
February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)
Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
The Journal of Antimicrobial Chemotherapy
|
January 23, 2019
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353
Amesika N Nyaku, Lu Zheng, Roy M Gulick, et al.
The Journal of Antimicrobial Chemotherapy
|
June 6, 2018
Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals
Tailah Bernardo de Almeida, Marcelo Costa Velho Mendes de Azevedo, Jorge Francisco da Cunha Pinto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 31, 2001
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy
P G Pappas, J R Perfect, G A Cloud, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 19, 2008
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
C Bradley Hare, John Mellors, Amy Krambrink, et al.
Clinical Pharmacology and Therapeutics
|
April 22, 2019
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Zeruesenay Desta, Roseann S Gammal, Li Gong, et al.
Molecular Psychiatry
|
September 6, 2024
A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder
Marion M Friske, Eva C Torrico, Maximilian J W Haas, et al.
Page
of 55